Seeking Alpha

Amarin Pharmaceuticals (AMRN) +15.5% premarket as U.S. patent examiners appear poised to approve...

Amarin Pharmaceuticals (AMRN) +15.5% premarket as U.S. patent examiners appear poised to approve a family of key patents that could protect its AMR101 prescription fish oil pill from generic competition through 2030. Jefferies is bullish on the prospects for approval, reiterating its Buy rating on the shares and raising its target price to $26 from $24.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)